Titan Pharmaceuticals, Inc.
TTNP
$3.70
-$0.09-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.71M | -5.89M | -5.46M | -4.95M | -5.57M |
| Total Depreciation and Amortization | 5.00K | 8.00K | 35.00K | 71.00K | 112.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.00K | 47.00K | -1.28M | -1.01M | -719.00K |
| Change in Net Operating Assets | 823.00K | 211.00K | -61.00K | 87.00K | -916.00K |
| Cash from Operations | -3.88M | -5.62M | -6.76M | -5.81M | -7.09M |
| Capital Expenditure | -- | -2.00K | -2.00K | -2.00K | -2.00K |
| Sale of Property, Plant, and Equipment | -- | 506.00K | 734.00K | 734.00K | 734.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 504.00K | 732.00K | 732.00K | 732.00K |
| Total Debt Issued | -- | 0.00 | 750.00K | 750.00K | 750.00K |
| Total Debt Repaid | -- | 0.00 | -250.00K | -250.00K | -250.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 406.00K | 9.50M | 9.50M | 9.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -62.00K | -- | -- | -- | -- |
| Cash from Financing | -62.00K | 406.00K | 10.00M | 10.00M | 10.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.94M | -4.71M | 3.97M | 4.93M | 3.64M |